Tandem Diabetes Care (NASDAQ:TNDM) Trading Down 6.1%

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Free Report) were down 6.1% during mid-day trading on Monday . The stock traded as low as $33.01 and last traded at $33.25. Approximately 251,865 shares were traded during trading, a decline of 86% from the average daily volume of 1,860,080 shares. The stock had previously closed at $35.41.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TNDM shares. StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Thursday, March 21st. Citigroup lifted their target price on shares of Tandem Diabetes Care from $25.00 to $31.00 and gave the company a “neutral” rating in a report on Friday, March 15th. Finally, Stifel Nicolaus upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and lifted their target price for the company from $24.00 to $37.00 in a report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $36.36.

Check Out Our Latest Research Report on Tandem Diabetes Care

Tandem Diabetes Care Price Performance

The firm has a market capitalization of $2.20 billion, a P/E ratio of -9.74 and a beta of 1.12. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The firm has a 50-day moving average of $27.37 and a 200-day moving average of $23.83.

Tandem Diabetes Care (NASDAQ:TNDMGet Free Report) last released its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. As a group, analysts predict that Tandem Diabetes Care, Inc. will post -1.62 EPS for the current year.

Hedge Funds Weigh In On Tandem Diabetes Care

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its stake in Tandem Diabetes Care by 45.1% in the 1st quarter. BlackRock Inc. now owns 9,207,560 shares of the medical device company’s stock worth $373,919,000 after buying an additional 2,861,120 shares in the last quarter. Vanguard Group Inc. increased its stake in Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock worth $207,708,000 after buying an additional 18,571 shares in the last quarter. Eminence Capital LP increased its stake in Tandem Diabetes Care by 76.1% in the 3rd quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock worth $114,028,000 after buying an additional 2,372,458 shares in the last quarter. State Street Corp increased its stake in Tandem Diabetes Care by 9.2% in the 2nd quarter. State Street Corp now owns 2,257,428 shares of the medical device company’s stock worth $55,397,000 after buying an additional 190,499 shares in the last quarter. Finally, Bellevue Group AG increased its stake in Tandem Diabetes Care by 16.7% in the 2nd quarter. Bellevue Group AG now owns 2,092,934 shares of the medical device company’s stock worth $51,361,000 after buying an additional 299,171 shares in the last quarter.

Tandem Diabetes Care Company Profile

(Get Free Report)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Further Reading

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.